Hepatic Impairment Trial of Obeticholic Acid
Completed · Phase 1
Conditions studied: Hepatic Impairment
In brief
This is a phase 1 study to evaluate the safety of a single 10 mg dose of obeticholic acid (OCA) in healthy volunteers and patients with liver disease.
Key facts
- Study ID
- NCT01904539
- Run by
- Intercept Pharmaceuticals
- People needed
- 32
- Starts
- 2013-06-01
- Expected to finish
- 2013-10-01
- Last updated by the study team
- 2013-10-24
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Clinical Pharmacology of Miami, Inc. — Miami, Florida, United States
- Orlando Clinical Research Center — Orlando, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.